Carboplatin-containing regimens are sometimes preferred for patients with advanced non-small cell lung cancer.
Methods
Eighty-three patients with stage III-IV non-small cell lung cancer received 3 to 4 cycles of carboplatin AUC 5 on day 2 and gemcitabine 1250 mg/m2 on days 1 and 8 every 21 days.
Results
The overall response rate was 43.4%. Results obtained from elderly and non-elderly groups were compared using the logrank method. Median overall survival and progression-free survival were 11 and 7 months, respectively (12 and 7 months, non-elderly group; 6.5 and 5 months, elderly group, P = 0.28 and 0.25 respectively). Grade 3–4 toxicity included neutropenia, thrombocytopenia, anemia, nausea/vomiting, and diarrhea. Incidences of grade 3–4 toxicity were similar for elderly and non-elderly patients.
Conclusions
Data confirm that carboplatin-gemcitabine is an active and well-tolerated regimen in advanced non-small cell lung cancer and could be investigated in elderly patients.
ParkinD., BrayF., FerlayJ., PisaniP.: Estimating the world cancer burden: Globocan 2000. Int J Cancer, 94: 153–1536, 2001.
2.
GridelliC., MaioneP., RossiA., CiardielloF., RabenD.: Treatment of locally advanced non-small cell lung cancer in the elderly. Curr Opin Oncol, 17: 130–134, 2005.
3.
PfisterD.G., JohnsonD.H., AzzoliC.G., SauseW., SmithT.J., BakerS., OlakJ., StoverD., StrawnJ.R., TurrisiA.T., SomerfieldM.R.: American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: update 2003. J Clin Oncol, 22: 330–353, 2004.
4.
LokichJ., AndersonN.Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol, 9: 13–21, 1998.
5.
RuddR.M., GowerN.H., SpiroS.G., EisenT.G., HarperP.G., LittlerJ.R., HattonM., JhonsonP.W., MartinW.M., RankinE.M., JamesL.E., GregoryW.M., OianW., LeeS.M.: Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J Clin Oncol, 23: 142–153, 2005.
6.
ZatloukalP., PetruzelkaL., ZemanovaM., KolekV., SkrickovàJ., PesekM., FojtùH., GrygàrkovàI., SixtovàD., RoubecJ., HorenkovàE., HavelL., PrùsaP., NovàkovàL., SkàcelT., KùtaM.: Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer, 41: 321–331, 2003.
7.
BajettaF., StaniS.C., De CandiiD., ZaffaroniN., ZilemboN., CortinovisD., AglioneS., MarianiL., FormisanoB., BidoliP.: Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer. Ann Oncol, 14: 242–247, 2003.
8.
CarmichaelJ., AllerheiligenS., WallingJ.A phase I study of gemcitabine and carboplatin in non-small cell lung cancer. Semin Oncol, 23(Suppl 10): 55–59, 1996.
9.
NgE.W., SandlerA.B., RobinsonL., EinhornL.H.: A phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a Hoosier Oncology Group study. Am J Clin Oncol, 22: 550–553, 1999.
10.
CarratoA., Garcia-GomezJ., AlberolaV., MassutiB.J., SanchezJ., JuanO., Diaz-FernandezN., GalanA., Rodriguez-LescureA., MeanaA., GonzalvezM.L., GallegoJ.: Carboplatin (CAR-BO) in combination with gemcitabine (GEM) in advanced non-small cell lung cancer (NSCLC). Comparison of two consecutive phase II trials using different schedules. Proc Am Soc Clin Oncol, abstr 1922, 1999.
11.
ParenteB., BarrosoA., CondeS., GuimaraesT., SeadaJ.: A prospective study of gemcitabine and carboplatin as first-line therapy in advanced non-small cell lung cancer: toxicity of a three- versus a four-week schedule. Semin Oncol, 28: 10–14, 2001.
12.
JovtisS., BrocatoN., BalbianiL., TemperleyG., CombaA., ZorA., RondinonM., AlmiraE., BrunoM., MaldonadoD., CavarraG., MartinezJ., OrlandoM.: First-line therapy with gemcitabine (G) and carboplatin (C) in patients (pts) with advanced non-small cell lung cancer (NSCLC): a phase II study. Proc Am Soc Clin Oncol, abstr 1969, 1999.
13.
GrossC., HolidayD., HamptonJ., KiemanH.: A combination therapy of gemcitabine (GEM) and carboplatin (CBDCA) in advanced stage non-small cell lung carcinoma (NSCLC). Proc Am Soc Clin Oncol, abstr 1955, 1999.
14.
TassinariD., FochessatiF., ArcangeliV., SartoriS., AgostiniV., FantiniM., GenestretiG., GrassiaS., IoliG., ImolaM., IorioD., MianulliA.M., MonticelliG., OliverioG., PanziniI., PapiM., PoggiB., PolselliA., PiluniS., TamburiniE., FattoriP.P., RavaioliA.: Carboplatin and gemcitabine in the palliative treatment of stage IV non-small cell lung cancer: definitive results of a phase II trial. Tumori, 90: 54–59, 2004.
15.
SederholmC.Gemcitabine (G) compared with gemcitabine plus carboplatin (GC) in advanced non-small cell lung cancer (NSCLC): a phase III study by the Swedish Lung Cancer Study Group (SLUSG). Proc Am Soc Clin Oncol, abstr 1162, 2002.
16.
CalvertA.H., NewellD.R., GumbrellL.A., O'ReillyS., BurnellM., BoxallF.E., SiddikZ.H., JudsonI.R., GoreM.E., WiltshawE.: Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol, 13: 2147–2148, 1995.
17.
GaultM.H., LongerichL.L., HarnettJ.D., WesolowskiC.: Predicting glomerular function from adjusted serum creatinine. Nephron, 62: 249–256, 1992.
18.
SocinskiM.A., SchellM.J., PetermanA., BakriK., YatesS., GittenR., UngerP., LeeJ., LeeJ.H., TynanM., MooreM., KiesM.S.: Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol, 5: 1335–1343, 2002.
19.
IanE., SmithE., O'BrienM.E.R., TalbotD.C., NicolsonM.C., MansiJ.L., HickishT.F., NortonA., AshleyS.: Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine and cisplatin. J Clin Oncol, 19: 1336–1343, 2001.
20.
BalducciL.: Geriatric oncology: Challenges for the new century. Eur J Cancer, 36: 1741–1754, 2000.
21.
LangerC.J., ManolaJ., BernardoP., KuglerJ.W., BonomiP., CellaD., JohnsonD.H.: Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst, 94: 173–181, 2002.
22.
ChenY.M., PerngR.P., LeeY.C., ShihJ.F., LeeC.S., TsaiC.M., Whang-PengJ.: Paclitaxel plus carboplatin, compared to paclitaxel plus gemcitabine, shows equal efficacy while more cost-effectiveness: a randomized study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated. Ann Oncol, 13: 108–115, 2002.
23.
ChenY.M., PerngR.P., ShihJ.F., LeeY.C., LeeC.S., TsaiC.M., Whang-PengJ.: A randomized phase II study of weekly paclitaxel or vinorelbine in combination with cisplatin against inoperable non-small-cell lung cancer previously untreated. Br J Cancer, 90: 359–365, 2004.
24.
KellyK., GiarrittaS., AkerleyW., HeskethP., WozniakA., AlbainK., CrowleyJ., GandaraD.R.: Should older patients (Pts) receive combination chemotherapy for advanced stage non-small cell lung cancer (NSCLC)? An analysis of Southwest Oncology trials 9509 and 9308 [abstract]. Proc Am Soc Clin Oncol, 20: a1313, 2001.
25.
GridelliC., PerroneF., GalloC., CigolariS., RossiA., PiantedosiF., BarberaS., FerraùE., PiazzaF., RosettiF., ClericiM., BertettoO., RobbiatiS.F., FrontiliL., SaccoC., CastiglioneF., FavarettoA., NovelloS., MigliorinoM.R., GaspariniG., GalettaD., IaffaioliR.V., GebbiaV.: Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst, 95: 362–372, 2003.
26.
ShepherdF.A., AbrattR.P., AndersonH., GatzmeierU., AnglinG., IglesiasJ.: Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer. Semin Oncol, 24(suppl): S50–55, 1997.
27.
FriedL.P., TangemC.M., WalstonJ., NewmanA.B., HirschC., GottdienerJ., SeemanT., TracyR., KopW.J., BurkeG., McBurnieM.A.: Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci, 56: 146–156, 2001.
28.
GridelliC.: Treatment of advanced non-small cell lung cancer in the elderly: from best supportive care to the combination of platin-based chemotherapy and target therapies. J Clin Oncol, 26: 13–15, 2008.
29.
ChenY.M., PerngR.P., ShihJ.F., TsaiC.M., Whang-PengJ.: Chemotherapy for non-small cell lung cancer in elderly patients. Chest, 128: 132–139, 2005.
30.
CostaG.J., FernandesA.L., PereiraJ.R., CurtisJ.R., SantoroI.L.: Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC). Lung Cancer, 53: 171–176, 2006.
31.
Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J, 311: 899–909, 1995.
32.
HottaK., MatsuoK., UeokaH., KiuraK., TabataM., TanimotoM.: Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small cell lung cancer. J Clin Oncol, 22: 3852–3859, 2004.
33.
ArdizzoniA., BoniL., TiseoM., FossellaF.V., SchillerJ.H., PaesmansM., RadosavljevicD., PaccagnellaA., ZatloukalP., MazzantiP., BissetD., RosellR.: Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst, 99: 828–829, 2007.
34.
GiorgioC.G., PappalardoA., RussoA., GiuffridaD., SantiniD., PetraliaG., CastorinaS., NunzioR., FaillaG., BordonaroR.: A phase II study of carboplatin and paclitaxel as first-line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer, 51: 357–362, 2006.
35.
InoueA., UsuiK., IshimotoO., MatsubaraN., TanakaM., KanbeM., GomiK., KoinumaroS., SaijoY., NukiwaT.: A phase II study of weekly paclitaxel combined with carboplatin for elderly patients with advanced non-small cell lung cancer. Lung Cancer, 52: 83–87, 2006.
36.
EdelmanM.J., QuamH., MullinsB.Interaction of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell lines. Cancer Chemother Pharmacol, 48: 141–144, 2001.
